First, it isn't FDA-approved. The fine print on the July 2026 press release explicitly states the product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease—a disclaimer real FDA-approved prescription drugs never carry. Visit reliefta.com and you’ll see Reliefta™ is an existing direct-to-consumer cannabinoid brand selling hemp balms, THC/CBD fruit chews, and a $49.96 multi-cannabinoid wellness patch online since at least 2024. Despite claims of a "joint commercialization pathway" into "healthcare e-prescribing networks," neither reliefta.com nor 11 Three LLC’s website even mentions UNVC as a partner, distributor, or co-owner.
https://www.otcmarkets.com/file/company/finan...22/content
Second, UNVC's Q3 2026 report (filed November 10, 2026) rules out any hidden post-quarter breakthrough. Under U.S. GAAP (ASC 855), management must disclose any material, binding contract, joint venture, or product launch occurring between the September 30 quarter-end and the November 10 filing date. On page 22, Note 9 certifies there were "no subsequent events requiring recognition or disclosure"—putting on the legal record that zero binding deals occurred during that 41-day window, alongside zero signed contracts, NDC codes, or licenses with 11 Three LLC in the Q3 filings.
In microcap stocks, press releases and social media posts are marketing; financial footnotes are legal representations. Between an existing online cannabinoid patch and Note 9 confirming zero material subsequent events, the filings separate what is legally binding from promotional noise.
Disclaimer — For informational and educational purposes only. Based on publicly available OTC Markets filings, press releases, and product websites. Not financial or legal advice. Always verify filings independently and do your own due diligence.
PL